New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
11:15 EDTINOInovio upgraded to Buy from Hold at Aegis
Aegis upgraded Inovio to Buy following positive top-line data from the clinical trial of its lead human papillomavirus DNA-based vaccine, VGX-3100, in patients with high-grade cervical dysplasia. Price target raised to $19 from $10.
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for INO

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use